Preparation and bioevaluation of a 99mTc-labeled small-molecular radiotracer for PD-L1 imaging DOI
Xiang Xu, Yuanbing Mao, Peng Zhou

et al.

Journal of Radioanalytical and Nuclear Chemistry, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 30, 2024

Language: Английский

Demystifying the Role of Immuno PET-CT in Non-Small Cell Lung Cancer: Clinical Value and Research Trends DOI
Sobhan Vinjamuri,

Vineet Pant

Seminars in Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

2
The Use of Radiology Imaging in Monitoring Treatment Response to PD-1/PD-L1 Inhibitors in Head and Neck Squamous Cell Carcinomas DOI
Soha Mohammadi, Shaghayegh Khanmohammadi,

Nima Taghizadeh Mortezaei

et al.

Interdisciplinary cancer research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Fluorine-Containing Macrocyclic Peptides and Peptidomimetics DOI Creative Commons
Neshat Rozatian, Stefan Roesner

Organic Chemistry Frontiers, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

This review covers recent advances in the synthesis and application of fluorine-containing macrocyclic peptides peptidomimetics.

Language: Английский

Citations

0
Advancements in Nuclear Imaging Using radiolabeled Nanobody tracers to support Cancer Immunotherapy DOI Creative Commons
Katty Zeven, Yoline Lauwers, Lynn De Mey

et al.

Immunotherapy Advances, Journal Year: 2024, Volume and Issue: 4(1)

Published: Jan. 1, 2024

The evolving landscape of cancer immunotherapy has revolutionized treatment. However, the dynamic tumor microenvironment led to variable clinical outcomes, indicating a need for predictive biomarkers. Noninvasive nuclear imaging, using radiolabeled modalities, aided in patient selection and monitoring their treatment response. This approach holds promise improving diagnostic accuracy, providing more personalized regimen, enhancing Nanobodies or single-domain antibodies, derived from camelid heavy-chain allow early timepoint detection targets with high target-to-background ratios. To date, plethora nanobodies have been developed imaging tumor-specific antigens, immune checkpoints, cells, both at preclinical level. review comprehensively outlines recent advancements nanobody-based on levels. Additionally, impact expected future use radiopharmaceuticals supporting diagnosis follow-up are discussed.

Language: Английский

Citations

2
Preparation and bioevaluation of a 99mTc-labeled small-molecular radiotracer for PD-L1 imaging DOI
Xiang Xu, Yuanbing Mao, Peng Zhou

et al.

Journal of Radioanalytical and Nuclear Chemistry, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 30, 2024

Language: Английский

Citations

0